Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McClellan Urges Rigor In Pharmacogenomic R&D: Less Art, More Science

This article was originally published in The Gray Sheet

Executive Summary

Linking microarray results to clinical outcomes will provide a more stable scientific platform for product development, FDA Commissioner Mark McClellan emphasized during an inaugural speech at the National Cancer Institute Director's Seminar Series

You may also be interested in...



Genomic Patent Exclusivity Tackled By NIH “Best Practices” Draft Guidance

NIH is floating a three-page draft guidance on best practices for the licensing of genomic inventions

Genomic Patent Exclusivity Tackled By NIH “Best Practices” Draft Guidance

NIH is floating a three-page draft guidance on best practices for the licensing of genomic inventions

Genetic Test Reimbursement Issues Get Top Billing On SACGHS Priority List

Concerns that inadequate genetic test reimbursement could hinder lab adoption of the technology have spurred the HHS Secretary's Advisory Committee on Genetics, Health & Society to rank the issue first on its list of priorities for in-depth analysis

Related Content

UsernamePublicRestriction

Register

MT019715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel